Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Predictive factors for successful treatment-free remission in CML

Fadi Haddad • 7 Dec 2025
ASH 2025
Chronic Myeloid Leukemia Leukemia Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib

Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a pooled analysis evaluating predictive factors for successful treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML). The analysis found sustained deep molecular remission, particularly of long duration, as the strongest predictor of durable TFR. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Fadi Haddad

A Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia
2:21
A Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia
Fadi Haddad • 7 Dec 2025
Second-line therapy outcomes in CML after frontline second-generation TKI failure
2:36
Second-line therapy outcomes in CML after frontline second-generation TKI failure
Fadi Haddad • 7 Dec 2025
Blinatumomab and ponatinib in newly diagnosed Ph+ ALL: updates from a Phase II trial
2:32
Blinatumomab and ponatinib in newly diagnosed Ph+ ALL: updates from a Phase II trial
Fadi Haddad • 11 Dec 2023
Dasatinib plus venetoclax in ECP-CML: insights from a Phase II study
4:49
Dasatinib plus venetoclax in ECP-CML: insights from a Phase II study
Fadi Haddad • 11 Dec 2023

Related Videos

HMAs or chemotherapy with venetoclax and gilteritinib for FLT3-mutated AML
4:13
HMAs or chemotherapy with venetoclax and gilteritinib for FLT3-mutated AML
Fadi Haddad • 17 Dec 2025
TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications
2:36
TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications
Fadi Haddad • 7 Dec 2025
Decoding DDX41: clinical impact of germline and somatic mutations in high-risk myeloid neoplasms
3:06
Decoding DDX41: clinical impact of germline and somatic mutations in high-risk myeloid neoplasms
Fadi Haddad • 7 Dec 2025
Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study
4:03
Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study
Fadi Haddad • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals